Is colistin effective in the treatment of infections caused by multidrug-resistant (MDR) or extremely drug-resistant (XDR) gram-negative microorganisms in children?


ÖZSÜREKCİ Y., AYKAÇ K., CENGİZ A. B., BAYHAN C., SANCAK B., KARADAĞ ÖNCEL E., ...More

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, vol.85, no.2, pp.233-238, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 85 Issue: 2
  • Publication Date: 2016
  • Doi Number: 10.1016/j.diagmicrobio.2016.02.017
  • Journal Name: DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.233-238
  • Keywords: Colistin, Childhood, Bacterial resistance, Multidrug resistant (MDR), Extremely drug resistant (XDR), INTENSIVE-CARE-UNIT, PSEUDOMONAS-AERUGINOSA, ACINETOBACTER-BAUMANNII, NOSOCOMIAL INFECTIONS, INTRAVENOUS COLISTIN, CYSTIC-FIBROSIS, BACTERIAL-INFECTIONS, COMBINATION THERAPY, PEDIATRIC-PATIENTS, VS. COLISTIN
  • Hacettepe University Affiliated: Yes

Abstract

The increasing incidence of infections caused by multidrug-resistant (MDR) or extremely drug-resistant (XDR) gram-negative organisms has led to the reemergence of colistin use. Clinical and demographic data were collected on 94 pediatric patients diagnosed with MDR or XDR gram-negative infections and treated with either a colistin-containing regimen (colistin group) or at least one antimicrobial agent other than colistin (noncolistin group). The overall clinical response rates were 65.8% in the colistin group and 70.0% in the noncolistin group (P = 0.33). The infection-related mortality rates were 11% in the colistin group and 13.3% in the noncolistin group (P = 0.74). There was no statistically significant difference in nephrotoxicity in the colistin and noncolistin groups. Colistin therapy was at least as effective and as safe as beta-lactam antibiotics or quinolones, with or without aminoglycosides, in the treatment of infections caused by gram-negative organisms and may be a therapeutic option in children. (C) 2016 Elsevier Inc. All rights reserved.